Trial
NCT05859724
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Yellow Jersey Therapeutics AG
Collaborators
—
Condition
Atopic Dermatitis
Intervention
NM26-2198
Why stopped
Asset acquisition by Johnson \& Johnson. Minimum study objectives necessary to inform safety, tolerability, and dose selection for Phase 2 dose-ranging evaluation of NM26-2198 were achieved, with full completion of all healthy volunteer cohorts.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-05